Shopping Cart
- Remove All
- Your shopping cart is currently empty
Farletuzumab (MORAb-003) is a humanized monoclonal antibody with a high affinity for folate receptor-α (FRα), acting as a potent inhibitor of FRα and impeding the growth of cells that overexpress this receptor, making it useful for cancer research.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $372 | In Stock | |
5 mg | $933 | In Stock | |
10 mg | $1,490 | In Stock | |
25 mg | $2,190 | In Stock | |
50 mg | $2,970 | In Stock | |
100 mg | $3,930 | In Stock |
Description | Farletuzumab (MORAb-003) is a humanized monoclonal antibody with a high affinity for folate receptor-α (FRα), acting as a potent inhibitor of FRα and impeding the growth of cells that overexpress this receptor, making it useful for cancer research. |
In vitro | In CHO-FR cells, Farletuzumab (MORAb-003; 0-10 µg/mL) inhibits FRα-dependent cell growth and increases folate EC50 in a dose-dependent manner[1]. In IGROV-1 cells (0.1-100 µg/mL; 1 h), Farletuzumab mediates tumor cytotoxicity in vitro through complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC)[1]. In CHO-FR cells (0-10 µg/mL), Farletuzumab inhibits the phosphorylation of proteins by Lyn kinase, a member of the src family of kinases, thereby blocking an FRα-mediated signaling pathway[1]. |
Alias | MORAb-003 |
Molecular Weight | 145.36 kDa |
Cas No. | 896723-44-7 |
Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.